d-Nav

02/07/2024

Gene Baker has lived with type 2 diabetes for 20 years. He has used multiple medications and combinations of therapies to treat his condition over this period of time. Understanding that diabetes is a progressive condition, and some therapies eventually stop working, he came to point where he needed a new option.

He decided to try the d-Nav Insulin Management System and has been nothing but happy with results! Gene kindly sat down with us recently and shared his d-Nav experience. You can look forward to another video from our conversation where he shares his ups and downs with diabetes and strategies for staying on track. Thank you so much, Gene!

Gene Baker has lived with type 2 diabetes for 20 years. He has used multiple medications and combinations of therapies to treat his condition over this period of time.

01/23/2024

A new year and an exciting partnership to announce! Our new partner, TempraMed, is at the forefront of creating and delivering groundbreaking personal storage solutions for injectable medications. Looking forward to doing great things together!

Hygieia, creator of insulin management system, d-Nav, announces a new partnership with TempraMed, a manufacturer of insulin insulin storage solutions. This relationship brings the innovative technologies of both companies to a much broader audience, helping more people simplify and effectively manag...

12/19/2023

Seasons Greeting to all! Check out our year-end 2023 d-Nav Reporter:
https://conta.cc/41wNHiV

12/07/2023

The Journal of Diabetes Obesity and Metabolism recently published our study showing results from patients who use d-Nav and check their glucose with a continuous glucose monitor (CGM). The study used the Time In Range (TIR) metric, which the measures the amount of time a person's glucose level remains within the recommended range. TIR was 70% for patients using d-Nav. These results demonstrated favorable glucose levels that are very comparable with results from automated insulin delivery (AID) systems, also known as artificial pancreas systems. Great work Kevin J. Williams MD, Eran Bashan PhD, Caitlin Kruse, Sajitha Sritharan, Israel Hodish MD!

Diabetes, Obesity & Metabolism is an interdisciplinary journal for clinical & experimental pharmacology and therapeutics relating to metabolic & endocrine disease.

11/23/2023

From our family to yours, we want to wish you a happy and safe day of gratitude! The holiday is all about being thankful for what we have, and we are grateful for you! We appreciate your support and trust in us. Happy Thanksgiving from the d-Nav team!

11/14/2023

We are taking you right to the source on this World Diabetes Day. The International Diabetes Federation’s Know Your Risk campaign offers a test to determine your risk for diabetes. If you know you have diabetes, it is critical to maintain good glucose level control to avoid complications.

This we encourage you to of type 2 diabetes. Take the online test and share it with your network so that more people around the world can take steps to delay or prevent the condition - https://bit.ly/WDDRiskAssessmentTool

11/07/2023

Our very own Zoe Heineman has once again has proven her determination and grit. She completed her 9th New York Marathon this past weekend!

A few marathons ago, Zoe shared insights into how she manages her diabetes while training and competing with Diabetes Voice. You can access that article here: https://diabetesvoice.org/en/living-with-diabetes/nyc-marathon-going-the-distance-with-diabetes/

We are lucky to have Zoe as a member of our team, and we can't wait to see what amazing feats she accomplishes next. Congratulations, Zoe!

11/01/2023

November is . We will be sharing important facts about the pancreas and insulin production (and the lack thereof). Stay tuned for our upcoming posts!

10/31/2023

Let’s celebrate the sweetness of life and remember that with proper management, insulin and candy can coexist. Happy Halloween!

10/26/2023

It’s not always about what you eat or how much you exercise. A massive new study just released by Weill Cornell Medicine and the National Institutes of Health explores the influence that genetics has with type 2 diabetes. The team focused on 20 genes associated with type 2, out of the 290 areas in the genome that can contribute to diabetes.

In experiments of unprecedented scale, researchers at Weill Cornell Medicine and the NIH have advanced efforts to better understand and ultimately treat this common metabolic disease.

10/24/2023

Today the excellent healthcare news source, BioTuesdays, published a feature about Hygieia and the d-Nav Insulin Management Program. Thank you for the coverage and for reporting on the latest news about life science companies and clinical trial developments.

Closely-held Hygieia, a digital therapeutics company for insulin therapy, is reforming how physicians and people with type 2 diabetes manage insulin with its breakthrough proprietary mobile app, d-Nav, which autonomously adjusts insulin dose recommendations to correspond with a patient’s changing ...

10/23/2023

It's been one year since Physicians East in Greenville, North Carolina launched d-Nav. What a committed group of doctors, nurses, medical assistants, and patients! We are honored to be your partner.